Hemab Therapeutics Holdings, Inc. Common Stock
COAGNASDAQHealthcareBiotechnology
Previous close
$49.16
+$0.96 · +1.99%
COAG company overview
Regular session · ET · Market data may be delayed.
Company profile
Company websiteHemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology firm dedicated to transforming the treatment of blood coagulation disorders. Operating in the United States and Denmark, its mission is to enhance life and resilience for patients through innovative therapies. The company's leading pipeline candidate is HMB-001, a bispecific antibody. This asset is currently undergoing Phase 1/2 clinical trials for the preventive management of Glanzmann thrombasthenia and has progressed to Phase 2 for the prophylactic treatment of Factor VII deficiency. Additionally, Hemab is advancing HMB-002, a monovalent antibody, through Phase 1/2 clinical development. This drug is designed for the subcutaneous prophylactic treatment of Von Willebrand disease. Beyond these clinical assets, the company actively pursues numerous preclinical and discovery-stage programs. Established in 2020, Hemab Therapeutics Holdings, Inc. maintains its headquarters in Cambridge, Massachusetts.
- Industry
- Biotechnology
- Sector
- Healthcare
- Headquarters
- US
- CEO
- Benny Sorensen
- Listed since
- May 1, 2026
- Employees
- 59
Market position
Day range
Current $49.16
52-week range
Current $49.16
- Open
- $48.85
- Previous close
- $48.20
- Volume
- 391.76K
- 1.07× average
- Average volume
- 365.42K
- Average daily volume
- Market cap
- 2.3B USD
- Beta
- 1.85
- Market reference 1
- 50-day average
- $41.5072
- +18.44% above average
- 200-day average
- $36.221
- +35.72% above average
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- 846.3M USD
- P/E (TTM)
- -37.53×
- P/B (TTM)
- 3.26×
- P/S (TTM)
- 0×
- EV / EBITDA
- -12.12×
- Earnings yield
- -6.85%
- Free cash flow yield
- -6.59%
- Dividend yield
- 0.00%
Profitability & efficiency
- Gross margin
- 0.00%
- Operating margin
- 0.00%
- Net margin
- 0.00%
- Return on equity
- 36.18%
- Return on assets
- -32.81%
- Return on invested capital
- -37.82%
Financial health
- Debt / equity
- 0×
- Current ratio
- 18.03×
Earnings
- EPS beat rate
- 0%
- 0 beats, 2 misses, 0 met estimates
- Average EPS surprise
- -6.19%
- 2 comparable reports
- Latest EPS result
- -0.8
- Estimate -0.73 · Miss by 9.22%
EPS: actual versus estimate
Recent quarterly results
Analyst ratings
Third-party consensus; not a GoAI recommendation.
Analyst price target
Average target
$51.40
4.56% upsideRating distribution
3 ratingsLimited analyst sample: 3 ratings. Interpret the distribution with caution.
COAG peers
ETFs holding COAG
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI26.42M0.00%2.3T USD0.03%$378.24+0.44%
Vanguard Extended Market ETFVXF9.69M0.01%93.7B USD0.05%$245.53+0.82%
Schwab U.S. Small-Cap ETFSCHA4.05M0.02%23.1B USD0.03%$34.83+0.52%
T. Rowe Price Small-Mid Cap ETFTMSL1.75M0.06%3B USD0.55%$43.59+0.60%
Schwab U.S. Broad Market ETFSCHB580.75K0.00%44.6B USD0.03%$29.61+0.48%
Vanguard Russell 2000 ETFVTWO338.37K0.00%17.4B USD0.06%$121.25+0.74%
Vanguard Russell 2000 Growth ETFVTWG33.19K0.00%1.7B USD0.06%$282.73+1.21%
Vanguard Russell 2000 Value ETFVTWV10.56K0.00%1.4B USD0.06%$198.38+0.34%Vanguard Morningstar Total Stock Market ETFVTI- Market value
- 26.42M
- Weight
- 0.00%
- AUM
- 2.3T USD
- Expense ratio
- 0.03%
- Price / 1D
- $378.24+0.44%
Vanguard Extended Market ETFVXF- Market value
- 9.69M
- Weight
- 0.01%
- AUM
- 93.7B USD
- Expense ratio
- 0.05%
- Price / 1D
- $245.53+0.82%
Schwab U.S. Small-Cap ETFSCHA- Market value
- 4.05M
- Weight
- 0.02%
- AUM
- 23.1B USD
- Expense ratio
- 0.03%
- Price / 1D
- $34.83+0.52%
T. Rowe Price Small-Mid Cap ETFTMSL- Market value
- 1.75M
- Weight
- 0.06%
- AUM
- 3B USD
- Expense ratio
- 0.55%
- Price / 1D
- $43.59+0.60%
Schwab U.S. Broad Market ETFSCHB- Market value
- 580.75K
- Weight
- 0.00%
- AUM
- 44.6B USD
- Expense ratio
- 0.03%
- Price / 1D
- $29.61+0.48%
Vanguard Russell 2000 ETFVTWO- Market value
- 338.37K
- Weight
- 0.00%
- AUM
- 17.4B USD
- Expense ratio
- 0.06%
- Price / 1D
- $121.25+0.74%
Vanguard Russell 2000 Growth ETFVTWG- Market value
- 33.19K
- Weight
- 0.00%
- AUM
- 1.7B USD
- Expense ratio
- 0.06%
- Price / 1D
- $282.73+1.21%
Vanguard Russell 2000 Value ETFVTWV- Market value
- 10.56K
- Weight
- 0.00%
- AUM
- 1.4B USD
- Expense ratio
- 0.06%
- Price / 1D
- $198.38+0.34%
Continue in GoAI
Research COAGresearch.disclaimer